Factors Associated With In-Hospital Mortality in Mycosis Fungoides Patients: A Multivariable Analysis
- PMID: 36120198
- PMCID: PMC9474264
- DOI: 10.7759/cureus.28043
Factors Associated With In-Hospital Mortality in Mycosis Fungoides Patients: A Multivariable Analysis
Abstract
Background Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL). Although it often has an indolent course, it can progress to more aggressive CTCL forms. There is sparse data in current literature describing specific clinical factors associated with in-hospital mortality in mycosis fungoides patients. An understanding of patients at greatest risk for in-hospital mortality can aid in developing recommendations for prophylaxis and empirical management. Aim We aim to characterize factors associated with in-hospital mortality in MF patients. Materials and methods The Nationwide Emergency Department Sample (NEDS) was queried for MF cases from 2006 to 2015. Baseline demographic and hospital characteristics were stratified based on survival outcomes. Multivariable logistic regression was used to identify factors associated with in-hospital mortality. Results A total of 57,665 patients with MF presenting to the ED between 2006 and 2015 were identified. Sézary syndrome, sepsis, and advanced age were associated with MF in-hospital mortality, while female sex was inversely associated. There was a downtrend in in-hospital mortality among MF patients presenting to the ED from 2006 to 2015. Conclusions Our study highlights factors crucial for risk-stratification for hospitalized MF patients.
Keywords: ctcl; cutaneous t-cell lymphoma; mortality; mycosis fungoides; neds; sepsis; sezary syndrome.
Copyright © 2022, King et al.
Conflict of interest statement
James B. Yu receives speaking and consulting fees from Boston Scientific and advisory board fees from Galera Pharmaceuticals. Michael Girardi is on the advisory board for Mallinckrodt and receives research funding support from AbbVie. None of these are relevant to the present work.
Similar articles
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049. J Am Acad Dermatol. 2014. PMID: 24438969 Review.
-
Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.J Med Internet Res. 2019 Jan 7;21(1):e11302. doi: 10.2196/11302. J Med Internet Res. 2019. PMID: 30617041 Free PMC article.
-
Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.Br J Dermatol. 2020 Mar;182(3):770-779. doi: 10.1111/bjd.18089. Epub 2019 Jul 28. Br J Dermatol. 2020. PMID: 31049926
-
The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.Br J Dermatol. 2003 Apr;148(4):709-18. doi: 10.1046/j.1365-2133.2003.05224.x. Br J Dermatol. 2003. PMID: 12752128
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.J Am Acad Dermatol. 2014 Feb;70(2):223.e1-17; quiz 240-2. doi: 10.1016/j.jaad.2013.08.033. J Am Acad Dermatol. 2014. PMID: 24438970 Review.
Cited by
-
Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy.Nat Commun. 2024 Jan 15;15(1):519. doi: 10.1038/s41467-024-44786-2. Nat Commun. 2024. PMID: 38225288 Free PMC article.
References
-
- Morbidity and causes of death in patients with cutaneous T-cell lymphoma in Finland. Väkevä L, Lipsanen T, Sintonen H, Ranki A. Acta Derm Venereol. 2017;97:735–738. - PubMed
-
- Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Pediatrics. 2009;123:0. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources